Premium
Personalised biopsy schedules based on risk of Gleason upgrading for patients with low‐risk prostate cancer on active surveillance
Author(s) -
Tomer Anirudh,
Nieboer Daan,
Roobol Monique J.,
Bjartell Anders,
Steyerberg Ewout W.,
Rizopoulos Dimitris
Publication year - 2021
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.15136
Subject(s) - prostate cancer , schedule , medicine , prostate specific antigen , biopsy , oncology , computer science , cancer , operating system
To develop a model and methodology for predicting the risk of Gleason upgrading in patients with prostate cancer on active surveillance (AS) and using the predicted risks to create risk-based personalised biopsy schedules as an alternative to one-size-fits-all schedules (e.g. annually). Furthermore, to assist patients and doctors in making shared decisions on biopsy schedules, by providing them quantitative estimates of the burden and benefit of opting for personalised vs any other schedule in AS. Lastly, to externally validate our model and implement it along with personalised schedules in a ready to use web-application.